Sleeping less than six hours a night could significantly raise a person’s risk of cancer or early death if they’re middle-aged and have high blood pressure, type 2 diabetes, heart disease or a history of stroke, according to work published in the Journal of the American Heart Association.

An updated meta-analysis centered around the role marine omega-3 supplementation in CVD prevention suggests there may be a use for fish oil in cardiovascular medicine after all.

The FDA approved canagliflozin Sept. 30 to reduce the risk of end-stage kidney disease, worsening kidney function, CV death and hospitalization for heart failure in adults with type 2 diabetes and diabetic nephropathy.

A simplified cardiac risk score can identify plaque buildup and silent brain infarctions that could predict a serious stroke, acting as a red flag for patients without a history of CVD or other vascular problems.

A panel of 14 international scientists published a nutritional guideline in the Annals of Internal Medicine this month suggesting adults continue consuming both red meat and processed meats, basing the recommendation on a mega-review that found few adverse health effects with either product.

An economic analysis of COAPT data suggests edge-to-edge TMVR with the MitraClip device is a more affordable long-term treatment option than guideline-directed medical therapy alone for patients with severe secondary MR—but the steep cost of an index TMVR procedure might eclipse that benefit.

The higher the dosage of cholesterol-lowering statins, the greater a patient’s risk of developing osteoporosis, according to work published in the Annals of Rheumatic Diseases.

CVS Pharmacy announced Sept. 28 it would be suspending the sales of all Zantac-brand and CVS Health-brand ranitidine products until further notice, pending the results of an FDA investigation.